tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

REPL Stock Latest News

Replimune price target raised to $14 from $13 at Piper Sandler
The FlyReplimune price target raised to $14 from $13 at Piper Sandler
9h ago
REPL
Replimune amends Hercules loan, strengthens funding runway
PremiumCompany Announcements
Replimune amends Hercules loan, strengthens funding runway
2d ago
8K
REPL
Replimune reports Q3 EPS (77c), consensus (82c)
PremiumThe Fly
Replimune reports Q3 EPS (77c), consensus (82c)
2d ago
REPL
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference
PremiumCompany Announcements
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference
24d ago
8K
REPL
Replimune Group Reports Increased Losses Amid R&D Expansion
PremiumCompany Announcements
Replimune Group Reports Increased Losses Amid R&D Expansion
3M ago
REPL
Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position
PremiumRatingsPositive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position
3M ago
REPL
Replimune reports Q2 EPS (90c), consensus (79c)
Premium
The Fly
Replimune reports Q2 EPS (90c), consensus (79c)
3M ago
REPL
Replimune upgraded to Market Perform from Underperform at BMO Capital
Premium
The Fly
Replimune upgraded to Market Perform from Underperform at BMO Capital
3M ago
REPL
Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
PremiumCompany Announcements
Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
3M ago
REPL
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
PremiumCompany Announcements
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
3M ago
REPL
Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
PremiumCompany Announcements
Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
3M ago
REPL
Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
PremiumCompany Announcements
Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
3M ago
REPL
Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
PremiumCompany AnnouncementsReplimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
3M ago
REPL
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
Premium
Company Announcements
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
3M ago
REPL
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
Premium
Company Announcements
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
3M ago
BMY
REPL
Replimune Group’s RP1 Resubmission Boosts Approval Odds and Buy Rating
PremiumRatings
Replimune Group’s RP1 Resubmission Boosts Approval Odds and Buy Rating
3M ago
REPL
Replimune upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
Replimune upgraded to Buy from Neutral at H.C. Wainwright
3M ago
REPL
Genelux price target raised to $20 from $10 at Maxim
PremiumThe Fly
Genelux price target raised to $20 from $10 at Maxim
4M ago
GNLX
REPL
Cautious Outlook on Replimune Group Amid FDA Uncertainties and Potential Risks
PremiumRatings
Cautious Outlook on Replimune Group Amid FDA Uncertainties and Potential Risks
4M ago
REPL
Piper upgrades Replimune to Overweight on ‘very pleasant surprise’
PremiumThe FlyPiper upgrades Replimune to Overweight on ‘very pleasant surprise’
4M ago
REPL
Replimune upgraded to Overweight from Neutral at Piper Sandler
Premium
The Fly
Replimune upgraded to Overweight from Neutral at Piper Sandler
4M ago
REPL
Replimune Group’s FDA Resubmission for RP1 Accepted
Premium
Company Announcements
Replimune Group’s FDA Resubmission for RP1 Accepted
4M ago
8K
REPL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >